Latest Period
Q4 2025
Security Snapshot
Ventyx Biosciences, Inc. - Common stock, par value $0.0001 per share (VTYX) Institutional Ownership
CUSIP: 92332V107
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
138
Shares (Excl. Options)
52,225,020
Price
$9.03
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common stock, par value $0.0001 per share
- Symbol
- VTYX
- Shares outstanding
- 71,364,430
- Price per share
- $14.00
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 52,225,020
- Total reported value
- $471,585,552
- % of total 13F portfolios
- 0%
- Share change
- +7,037,465
- Value change
- +$103,494,344
- Number of holders
- 138
- Price from insider filings
- $14.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- VTYX - Ventyx Biosciences, Inc. - Common stock, par value $0.0001 per share is tracked under CUSIP 92332V107.
- 138 institutions reported positions in Q4 2025.
- 13 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 138 to 1 between Q4 2025 and Q1 2026.
- Reported value moved from $471,585,552 to $21,000.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 138 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 92332V107?
CUSIP 92332V107 identifies VTYX - Ventyx Biosciences, Inc. - Common stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue With The Right Next Step
- Latest 13F filings - identify new institutional portfolio moves.
- Latest Schedule 13D/13G reports - cross-check beneficial ownership events.
- All institutional ownership pages - compare nearby CUSIPs and holder concentration.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92332V107:
Significant Owners of Ventyx Biosciences, Inc. - Common stock, par value $0.0001 per share (VTYX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 9% | +55% | $58,381,906 | +$21,744,625 | 6,465,041 | +59% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| NSV Investments I, L.P. | 7.6% | $6,836,036 | 5,425,425 | Somasundaram Subramaniam | 10 Mar 2025 | |||
| GLAZER CAPITAL, LLC | 6.2% | $61,754,996 | 4,446,004 | Glazer Capital, LLC | 12 Feb 2026 | |||
| Mohan Raju | 6% | 0% | $39,622,524 | +$48,060 | 4,387,682 | +0.12% | Raju Mohan | 07 Jan 2026 |
| NSV Partners III LP | 5.7% | $5,153,368 | 4,089,975 | Subramaniam Somu | 28 Mar 2025 | |||
| VANGUARD GROUP INC | 5.3% | $11,725,822 | 3,769,997 | The Vanguard Group | 30 Sep 2025 | |||
| Point72 Asset Management, L.P. | 4.5% | -48% | $9,981,996 | -$8,351,669 | 3,209,645 | -46% | Point72 Asset Management, L.P. | 30 Sep 2025 |
| Sio Capital Management, LLC | 3.6% | -35% | $3,254,145 | -$1,844,819 | 2,582,655 | -36% | Sio Capital Management, LLC | 31 Mar 2025 |
| CITADEL ADVISORS LLC | 2% | $1,776,097 | 1,409,601 | Kenneth Griffin | 31 Mar 2025 | |||
| BlackRock, Inc. | 1.9% | $2,891,112 | 1,350,987 | BlackRock, Inc. | 30 Jun 2025 | |||
| BANK OF AMERICA CORP /DE/ | 1.4% | -73% | $1,280,978 | -$4,535,858 | 1,016,649 | -78% | BANK OF AMERICA CORP /DE/ | 31 Mar 2025 |
| Flynn James E | 0.76% | $673,769 | 534,737 | Deerfield Mgmt, L.P. | 31 Dec 2024 | |||
| MORGAN STANLEY | 0.3% | -95% | $2,143,343 | -$36,594,590 | 237,358 | -94% | Morgan Stanley | 31 Jan 2026 |
As of 31 Dec 2025, 138 institutional investors reported holding 52,225,020 shares of Ventyx Biosciences, Inc. - Common stock, par value $0.0001 per share (VTYX). This represents 73% of the company’s total 71,364,430 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Ventyx Biosciences, Inc. - Common stock, par value $0.0001 per share (VTYX) together control 60% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 9.1% | 6,484,558 | +65% | 4.2% | $58,555,559 |
| MORGAN STANLEY | 6% | 4,292,951 | +1661% | 0% | $38,765,348 |
| VANGUARD GROUP INC | 5.5% | 3,943,566 | +4.6% | 0% | $35,610,400 |
| BlackRock, Inc. | 4.4% | 3,142,440 | +166% | 0% | $28,376,233 |
| TANG CAPITAL MANAGEMENT LLC | 3.9% | 2,814,000 | -9.2% | 1.3% | $25,410,420 |
| BAKER BROS. ADVISORS LP | 3.3% | 2,349,280 | +130% | 0.12% | $21,213,998 |
| BRAIDWELL LP | 2.7% | 1,920,255 | 0.55% | $17,339,903 | |
| D. E. Shaw & Co., Inc. | 2.3% | 1,665,474 | +219% | 0.01% | $15,039,230 |
| MPM BIOIMPACT LLC | 2.3% | 1,639,061 | 1.7% | $14,800,721 | |
| CITADEL ADVISORS LLC | 2.2% | 1,563,611 | -17% | 0.01% | $14,119,407 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.7% | 1,203,997 | +14% | 0.03% | $10,872,093 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.6% | 1,118,275 | +64% | 0.01% | $10,098,023 |
| Point72 Asset Management, L.P. | 1.5% | 1,056,520 | -67% | 0.01% | $9,540,376 |
| 683 Capital Management, LLC | 1.5% | 1,040,000 | +4% | 0.78% | $9,391,200 |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 989,917 | -40% | 0.01% | $8,938,951 |
| Ikarian Capital, LLC | 1.3% | 958,704 | -27% | 1.1% | $8,657,097 |
| JANE STREET GROUP, LLC | 1.3% | 941,067 | +144% | 0.01% | $8,497,835 |
| GOLDMAN SACHS GROUP INC | 1.2% | 837,602 | +106% | 0% | $7,563,546 |
| ACADIAN ASSET MANAGEMENT LLC | 1.1% | 773,512 | +9.9% | 0.01% | $6,978,000 |
| DIMENSIONAL FUND ADVISORS LP | 1% | 742,544 | +76% | 0% | $6,702,415 |
| Balyasny Asset Management L.P. | 1% | 735,711 | 0.01% | $6,643,470 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1% | 722,355 | -0.87% | 0% | $6,526,279 |
| Artia Global Partners LP | 0.98% | 695,982 | 1% | $6,284,717 | |
| TUDOR INVESTMENT CORP ET AL | 0.82% | 583,611 | 0.03% | $5,270,007 | |
| STATE STREET CORP | 0.77% | 548,743 | +91% | 0% | $4,955,149 |
Institutional Holders of Ventyx Biosciences, Inc. - Common stock, par value $0.0001 per share (VTYX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1,500 | $21,000 | -$1,366,243 | $14.00 | 1 |
| 2025 Q4 | 52,225,020 | $471,585,552 | +$103,494,344 | $9.03 | 138 |
| 2025 Q3 | 43,853,431 | $136,378,109 | -$468,450 | $3.11 | 109 |
| 2025 Q2 | 44,427,101 | $95,066,026 | +$2,059,789 | $2.14 | 112 |
| 2025 Q1 | 44,413,797 | $51,071,272 | -$13,704,510 | $1.15 | 116 |
| 2024 Q4 | 54,449,340 | $119,241,531 | +$4,099,056 | $2.19 | 122 |
| 2024 Q3 | 52,481,458 | $114,411,828 | -$11,847,686 | $2.18 | 115 |
| 2024 Q2 | 57,252,817 | $132,254,360 | -$36,320,827 | $2.31 | 114 |
| 2024 Q1 | 58,990,812 | $323,851,608 | +$111,976,682 | $5.50 | 122 |
| 2023 Q4 | 43,247,569 | $106,821,389 | -$553,553,365 | $2.47 | 118 |
| 2023 Q3 | 54,583,406 | $1,895,690,669 | +$62,410,449 | $34.73 | 137 |
| 2023 Q2 | 52,627,413 | $1,726,219,124 | +$92,758,720 | $32.80 | 146 |
| 2023 Q1 | 49,748,691 | $1,666,552,448 | +$243,592,644 | $33.50 | 143 |
| 2022 Q4 | 42,351,969 | $1,388,715,670 | +$101,470,239 | $32.79 | 122 |
| 2022 Q3 | 39,299,041 | $1,371,090,008 | +$167,335,144 | $34.91 | 104 |
| 2022 Q2 | 34,630,744 | $423,528,800 | +$16,981,526 | $12.23 | 58 |
| 2022 Q1 | 33,233,009 | $448,438,000 | +$21,644,387 | $13.57 | 53 |
| 2021 Q4 | 30,695,789 | $601,183,000 | +$601,183,000 | $19.86 | 45 |